OCGN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 23.55%, SMA50 22.49%, SMA200 47.6%). The stock’s 14-day RSI is 71.57 (overbought), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.59% below its high and over 263.11% above its low. Average 10-day trading volume of 4.61 million shares is below the 3-month average of 7.80 million, indicating normal recent market interest.

Ocugen, Inc. has 312.30 million shares outstanding. The public float is 287.94 million shares, elevated short interest at 19.04% of float. This equals 54.76 million shares. The short ratio is 13.59 days. Institutional investors hold 16.89% of the float. Insiders own 1.49%. Musunuri Shankar holds 2.19 million shares, KIRK RANDAL J has 1.69 million shares and Zhang Junge has 1.08 million shares.

Ocugen, Inc. generated EPS of -$0.22 over the past year. Five-year average earnings growth is 32.82%. Wall Street analysts project EPS growth of 44.07% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.06. Next year's EPS is expected at $3.42. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 9 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $7.00. The high target offers 548.65% upside. The low target suggests 278.38% downside. The mean target is $8.10. This offers 337.84% upside. Ocugen, Inc. earnings surprise history is a mixed track record. The quarter that ended March 04, 2026, missed forecasts by 0.0%. The prior quarter beat by 14.71%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 14, 2024.

Ocugen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.31. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Ocugen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -14.59%, with price expected at $1.58 by May 14, 2026, within a range of $1.37 to $1.80 3-Month Outlook: Projected fall of -21.08%, reaching $1.46 by July 29, 2026, with a range of $1.36 to $1.54. 1-Year Outlook: Projected gain of 863.78%, with price at $17.83 by April 30, 2027, within a range of $18.55 to $21.26.

Ocugen, Inc. (NASDAQ:OCGN) shares are up 23.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ocugen, Inc. trading at a premium to the broader market with a P/E of -8.6. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.55, suggesting 254.05% upside. Our AI forecast model points to short-term weakness (-14.59% over two weeks), a medium-term fall (-21.08% over three months), and a longer-term gain (863.78% over one year), with expected trading ranges indicating moderate volatility.

Ocugen, Inc. trades at a P/E ratio of -8.6, slightly below the S&P 500 average, with a price-to-sales ratio of 143.31 and a price-to-book ratio of -47.96 indicating negative book value, which may reflect financial stress. The P/FCF stands at -11.07, also below market averages.

Ocugen, Inc. (NASDAQ:OCGN) closed at $1.85 USD, gaining $0.05 (2.78%) from the previous close of $1.80. The stock is currently mid-range between its 52-week high and low $0.64 and $2.73. With a market capitalization of about $626.25 million, Ocugen, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.31). Key stats such as the average daily volume over the past year has been around 7.91 million shares, in line with its 52-week average. Headquartered in Malvern, PA, Ocugen, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shankar Musunuri, the company employs approximately 95 people and listed since December 03, 2014. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.